Nasal immunization with compound 48/80-adjuvanted acellular pertussis vaccines is an effective strategy to induce pertussis-specific systemic and mucosal immunity.

ABSTRACT:

Purpose

Mast cell activating adjuvants induce vaccine-specific systemic and mucosal immunity when administered intranasally. Bordetella pertussis infects the respiratory tract and caused 0.45% childhood mortality in the United States before implementing pertussis vaccines. Pertussis infections are resurging. Immunity induced by current pertussis vaccines wanes quickly, possibly due to vaccine-induced T helper (Th) 2 and weak mucosal immunity. B. pertussis induces Th1, Th17, and mucosal immunoglobulin A (IgA) immunity, providing durable protection against disease. Next-generation pertussis vaccines that induce Th1, Th17, and IgA immunity may reduce the resurgence of pertussis. This study determined if nasal pertussis vaccines adjuvanted with the mast cell activator com

SUBMITTER: Church AH 

PROVIDER: S-EPMC12303703 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature